

PRODUCT INFORMATION




TPX-0005

Item No. 23397

CAS Registry No.: 1802220-02-5
Formal Name: (7S,13R)-11-fluoro-6,7,13,14-tetrahydro-7,13-dimethyl-1,15-etheno-1H-pyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one

Synonym: Repotrectinib
MF: C₁₈H₁₈FN₅O₂
FW: 355.4
Purity: ≥98%
UV/Vis.: λ_{max}: 222, 258 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

TPX-0005 is supplied as a crystalline solid. A stock solution may be made by dissolving the TPX-0005 in the solvent of choice, which should be purged with an inert gas. TPX-0005 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of TPX-0005 in these solvents is approximately 0.2 and 1 mg/ml, respectively.

Description

TPX-0005 is a multi-kinase inhibitor that inhibits TrkA, TrkB, and TrkC (IC₅₀s = 0.83, 0.05, and 0.1 nM, respectively) as well as C-ros oncogene 1 (ROS1; IC₅₀ = 0.07 nM).¹ It inhibits a variety of other kinases, including ALK, JAK2, LYN, Src, and FAK (IC₅₀s = 1.04, 1.04, 1.66, 5.3, and 6.96 nM, respectively). It inhibits proliferation of PC-9, H1975, 11-18, HCC4006, and HCC827 lung cancer cells (IC₅₀s = 100, 100, 150, 148, and 430 nM, respectively) with additive or synergistic effects when used in combination with gefitinib (Item No. 13166), afatinib (Item No. 11492), PF-299804 (dacomitinib; Item No. 9001879), or osimertinib. TPX-0005 (30 mg/kg) reduces tumor growth in PC-9 and H1975 mouse xenograft models and potentiates the effect of osimertinib in these models.

Reference

1. Karachaliou, N., Chaib, I., Cardona, A.F., *et al.* Common co-activation of AXL and CDCP1 in EGFR-mutation-positive non-small cell lung cancer associated with poor prognosis. *EBioMedicine* **29**, 112-127 (2018).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/22/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM